Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

BACKGROUND: It is estimated that up to a third of patients on opioid agonist therapy (OAT) have attention deficit hyperactivity disorder (ADHD). Treatment by ADHD medication, including a centrally acting stimulant (CAS) or atomoxetine is one of the essential approaches. This study evaluates the use...

Descripción completa

Detalles Bibliográficos
Autores principales: Vold, Jørn Henrik, Aas, Christer, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Halmøy, Anne, Johansson, Kjell Arne, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068965/
https://www.ncbi.nlm.nih.gov/pubmed/32164615
http://dx.doi.org/10.1186/s12888-020-02526-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068965/
https://www.ncbi.nlm.nih.gov/pubmed/32164615
http://dx.doi.org/10.1186/s12888-020-02526-y

Ejemplares similares